Lipotriches exagens

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023

Retrieved on: 
Monday, March 6, 2023
Webcast, SAN, Lipotriches exagens, Interest, Cryptocurrency

SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2022, after the market close on Monday, March 20, 2023.

Key Points: 
  • SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2022, after the market close on Monday, March 20, 2023.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).
  • A replay of the conference call will be available until Monday, April 3, 2023, at 11:59 PM ET (8:59 PM PT).
  • Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

Retrieved on: 
Monday, January 23, 2023
Arena Pharmaceuticals, Ligand Pharmaceuticals, University of California, Irvine School of Medicine, Biology, Pleasure, SAN, SVP, The Washington Campus Board of Directors, Organization, Doctor of Philosophy, University, University of California, Riverside, Management, Novartis, Lipotriches exagens, Biochemistry, Beckman Coulter

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023.

Key Points: 
  • SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023.
  • Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.
  • Dr. Nova was the co-founder, President & CEO of Genoptix, which was purchased by Novartis AG for $470 million in 2011.
  • “I am excited to welcome Tina as Executive Chair at Exagen.

Exagen Inc. Reports Third Quarter 2022 Results

Retrieved on: 
Monday, November 14, 2022
COVID-19, Growth, SAN, Laboratory, Rheumatology, R, Physician, Patient, Lupus, Janssen, Movement, Total, Annual report, XGN, CTD, Medicine, Webcast, Security (finance), Medicare, Interest, Precision medicine, Research, Therapy, PLA, Investment, Audit committee, Renewable energy, Video game, Tutoring, Pharmaceutical industry, Lipotriches exagens

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022.
  • Delivered 35,569 AVISE CTD tests, including AVISE Lupus, in the third quarter of 2022, a 12% increase over the third quarter of 2021.
  • Number of ordering healthcare providers totaled 2,287 in the third quarter of 2022, an increase of 16% over the third quarter of 2021.
  • Testing gross margin was 59.2% in the third quarter of 2022, compared to 53.7% in the third quarter of 2021.

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, Private Securities Litigation Reform Act, Laboratory, U.S. Securities and Exchange Commission, EST, Research, Ophthalmology, Vista, Precision medicine, SEC, Annual report, Solution, CA, XGN, Movement, Rheumatology, Conference, Medicare, Patient, Physician, Therapy, Security (finance), COVID-19, Pharmaceutical industry, Lipotriches exagens

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth quarter investor conferences.

Key Points: 
  • SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth quarter investor conferences.
  • The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine.Exagenis located inSan Diego Countywith clinical and research and development laboratories inVista, CA.
  • Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.
  • The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved.

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022

Retrieved on: 
Monday, October 31, 2022
GLOBE, Research, Physician, Interest, XGN, Review, Lipotriches exagens, Patient, Webcast, Precision medicine, SAN, Laboratory, CA, Pharmaceutical industry

SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022.

Key Points: 
  • SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022.
  • A replay of the conference call will be available until Monday, November 28, 2022, at 11:59 PM ET (8:59 PM PT).
  • Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13733098.
  • Exagen is located in San Diego County with clinical and research and development laboratories in Vista, CA.

Exagen Announces Appointment of John Aballi as CEO

Retrieved on: 
Monday, October 17, 2022
SAN, Physician, CAP, CA, U.S. Securities and Exchange Commission, Cell biology, Movement, CLIA, Medicine, Therapy, University of California, San Diego, SEC, California Baptist University, Growth, General manager, Laboratory, Employment, Annual report, Baptist University, COO, Patient, List of life sciences, MBA, Twitter, Research, Security (finance), Exact sciences, SVP, Cancer, Precision medicine, Private Securities Litigation Reform Act, Goal, Rheumatology, Medicare, XGN, Board, Breast cancer, CEO, Economics, Genomics, GLOBE, Novartis, COVID-19, Solution, Biochemistry, Vista, Management, Risk management, Fine chemical, Pharmaceutical industry, Lipotriches exagens

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.

Key Points: 
  • SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.
  • The Exagen Board has appointed Mr. Aballi as CEO, President, and a member of the Board.
  • I am delighted that John has agreed to lead the next phase of growth at Exagen, said Board Chair Brian Birk.
  • Im very excited to be joining Exagen as CEO, Mr. Aballi said.

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Retrieved on: 
Tuesday, October 4, 2022
Solution, Movement, Lipotriches exagens, American College of Rheumatology, Medicare, Prognosis, Rheumatoid arthritis, Physician, SEC, Research, Precision medicine, Private Securities Litigation Reform Act, Health, Twitter, American College, University of California, San Francisco, Osteoarthritis, COVID-19, Annual report, Â, XGN, CA, UCLA, SAN, Leadership, Vista, Rheumatology, Patient, Environment, Employment, Diagnosis, Degenerative disease, Laboratory, University, Therapy, GLOBE, Medical device, Pharmaceutical industry

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D.

Key Points: 
  • SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D.
  • In this role, Dr. Concoff will lead the companys rheumatoid arthritis medical initiatives, including the AVISE RADR platform (Rheumatoid Arthritis Drug Response).
  • Exagen is deeply committed to rheumatology where we believe there are significant unmet needs in the diagnosis, prognosis, and monitoring of autoimmune diseases, that our tests can uniquely address, said Ron Rocca, President and Chief Executive Officer, Exagen.
  • We are delighted to welcome Dr. Concoff to our Executive Leadership Team as we enter the next phase of innovation for Exagen.

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Retrieved on: 
Thursday, September 1, 2022
CA, COVID-19, CEO, Technology, Division, Research, SAN, Emory University, Doctor of Philosophy, Solution, Precision medicine, PACS, Physician, Area studies, SEC, Laboratory, XGN, Vista, Severe acute respiratory syndrome coronavirus 2, GLOBE, Medicare, Movement, Therapy, Twitter, Cell-bound complement activation products, Annual report, Private Securities Litigation Reform Act, COVID, Trial of the century, Patient, Emory School, Pharmaceutical industry, Nature, Lipotriches exagens, Rheumatology

Exagens clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection.

Key Points: 
  • Exagens clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection.
  • These efforts will assess the importance of long-term autoimmune monitoring in those patients experiencing lasting symptoms following acute pulmonary infection, including those caused by SARS-CoV-2.
  • Mathew Woodruff, PhD is a researcher at the Lowance Center for Human Immunology and the Division of Rheumatology at Emory School of Medicine.
  • We are excited to have partnered with Exagen on this important work investigating the origins of emerging self-targeted antibody responses in severe COVID-19.

Exagen Inc. Reports Second Quarter 2022 Results

Retrieved on: 
Thursday, August 4, 2022
Movement, U.S. Securities and Exchange Commission, Laboratory, Precision medicine, Investor relations, GLOBE, Lupus, CA, Private Securities Litigation Reform Act, CTD, SEC, Investment, Growth, Rheumatology, Security (finance), Research, Annual report, Patient, Review, COVID-19, Twitter, SAN, Therapy, XGN, Record, Webcast, Physician, Goal, Journal, Janssen, Solution, WellCare, Interest, Video game, Pharmaceutical industry, Medicare, Lipotriches exagens

Delivered a record 34,919 AVISE CTD tests, including AVISE Lupus, in the second quarter of 2022, a 5% increase over the second quarter of 2021 and a 13% increase over the first quarter of 2022.

Key Points: 
  • Delivered a record 34,919 AVISE CTD tests, including AVISE Lupus, in the second quarter of 2022, a 5% increase over the second quarter of 2021 and a 13% increase over the first quarter of 2022.
  • Our revenue resulting from the Janssen Agreement contributed no revenue in the second quarter of 2022, compared to $0.3 million in the second quarter of 2021.
  • Testing gross margin was 32.2% in the second quarter of 2022, compared to 56.3% in the second quarter of 2021.
  • For the second quarter of 2022, net loss was $13.3 million, compared to a net loss of $6.4 million for the second quarter of 2021.

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

Retrieved on: 
Thursday, August 4, 2022
Movement, Laboratory, Biomarker, Tiger, Precision medicine, CEO, Medicare, Trial of the century, GLOBE, CA, Private Securities Litigation Reform Act, SEC, Rheumatology, Research, Annual report, Patient, Vista, COVID-19, Gene expression profiling, Twitter, Rheumatoid arthritis, SAN, Gene expression, Therapy, Treatment, Lipotriches exagens, XGN, Physician, Solution, Biopsy, Disease, Medical imaging, Pharmaceutical industry

The goal of the Treatment stratIfication using Gene Expression profiling in Rheumatoid arthritis (TiGER) study is to assess whether certain biomarkers from synovial biopsies of inflamed joint tissue accurately predict response to antirheumatic medications.

Key Points: 
  • The goal of the Treatment stratIfication using Gene Expression profiling in Rheumatoid arthritis (TiGER) study is to assess whether certain biomarkers from synovial biopsies of inflamed joint tissue accurately predict response to antirheumatic medications.
  • Approximately 120,000 Americans are diagnosed with rheumatoid arthritis every year, with 2 million patients currently living with the disease.
  • Total rheumatoid arthritis therapeutic spending in the United States is $30B, with 70-80% of rheumatoid arthritis patients failing to reach low disease activity, leading to $18B in wasted therapeutic spending.
  • Most patients who deal with rheumatoid arthritis often need to try a variety of medications before finding the one that works.